Preparation and characterization of a novel chimeric antibody against human CD40 with the potential to inhibit Daudi cell proliferation.
5C11, a murine monoclonal antibody with a high specificity for human CD40 molecule, is a promising candidate for cancer targeting therapy. We have therefore attempted to construct a humanized antibody of 5C11 to minimize its immunogenicity for potential clinical use. A chimeric version of 5C11 (ch-5C11) was generated by transferring these mouse variable regions onto a human framework. This chimeric antibody retained reactivity to human CD40. In vitro, ch-5C11 could effectively inhibit B lymphoma Daudi cell proliferation, suggesting that it might have the potential to be developed for future clinical use.
Qu
Qiu-Xia
QX
Clinical Immunology Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ge
Yan
Y
Chen
Yong-Jin
YJ
Chen
Cheng
C
Qiu
Yu-Hua
YH
Zhang
Xue-Guang
XG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000494:pharmacology; D019013:CD40 Antigens / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D019013:CD40 Antigens; D007135:Immunoglobulin Variable Region